WashU and Siteman receive $11.6M SPORE grant for endometrial cancer research

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.

January 17, 2025

Vol.51 No.02

In Brief

NCI funds $11.6M “Route 66” SPORE in endometrial cancer

NCI has awarded researchers at Washington University School of Medicine in St. Louis a Specialized Programs of Research Excellence grant to spur new strategies to prevent and treat endometrial cancer.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer

Incyte announced early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors.

September 20, 2024

Vol.50 No.35

In Brief

Siteman to open building dedicated exclusively to cancer care

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, will open a new home for cancer care and welcome its first patients Sept. 30.

September 13, 2024

Vol.50 No.34